chemoimmunotherapy

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

By MedXY 08/25/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.

news Oncology Otorhinolaryngology

Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell Carcinoma

By MedXY 08/24/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.

Hematology-Oncology news

Challenging the Incurability Paradigm: 15-Year Data Suggests a Cure for Advanced Follicular Lymphoma

By MedXY 03/09/2026

The 15-year follow-up of the SWOG S0016 trial demonstrates that approximately 42% of patients with advanced follicular lymphoma may be cured with initial CHOP-based chemoimmunotherapy, with relapse rates dropping significantly after 15 years.

news Oncology Specialties

Immunosuppressive Roles of Tumour-Infiltrating B Cells in Intrahepatic Cholangiocarcinoma and Implications for Chemoimmunotherapy Outcomes

By MedXY 09/04/2025

This article reviews the immunosuppressive mechanisms of tumour-infiltrating B cells in intrahepatic cholangiocarcinoma (iCCA), their impact on prognosis, and potential to enhance chemoimmunotherapy efficacy by restoring B-cell function and promoting tertiary lymphoid structures.